Abstract:Herein, advancements in electroanalytical devices for the simultaneous detection of diverse breast cancer (BC) markers are demonstrated. This article identifies several important areas of exploration for electrochemical diagnostics and highlights important factors that are pivotal for the successful deployment of novel bioanalytical devices. We have highlighted that the limits of detection (LOD) reported for the multiplex electrochemical biosensor can surpass the sensitivity displayed by current clinical standards such as ELISA, FISH, and PCR. HER-2; a breast cancer marker characterised by increased metastatic potential, more aggressive development, and poor clinical outcomes; can be sensed with a LOD of 0.5 ng/ml using electrochemical multiplex platforms, which falls within the range of that measured by ELISA (from picogram/ml to nanogram/ml). Electrochemical multiplex biosensors are reported with detection limits of 0.53 ng/ml and 0.21 U/ml for MUC-1 and CA 15-3, respectively, or 5.8 × 10-3 U/ml for CA 15-3 alone. The sensitivity of electrochemical assays is improved when compared to conventional analysis of MUC-1 protein which is detected at 11-12 ng/ml, and ≤30 U/ml for CA 15-3 in the current clinical blood tests. The LOD for micro-ribonucleic acid (miRNA) biomarkers analyzed by electrochemical multiplex assays were all notedly superior at 9.79 × 10-16 M, 3.58 × 10-15 M, and 2.54 × 10-16 M for miRNA-155, miRNA-21, and miRNA-16, respectively. The dogma in miRNA testing is the qRT-PCR method, which reports ranges in the ng/ml level for the same miRNAs. Breast cancer exosomes, which are being explored as a new frontier of biosensing, have been detected electrochemically with an LOD of 103-108 particles/mL and can exceed detection limits seen by the tracking and analysis of nanoparticles (∼ 107 particles/ml), flow cytometry, Western blotting and ELISA, etc. A range of concentration at 78-5,000 pg/ml for RANKL and 16-1,000 pg/ml for TNF is reported for ELISA assay while LOD values of 2.6 and 3.0 pg/ml for RANKL and TNF, respectively, are demonstrated by the electrochemical dual immunoassay platform. Finally, EGFR and VEGF markers can be quantified at much lower concentrations (0.01 and 0.005 pg/ml for EGFR and VEGF, respectively) as compared to their ELISA assays (EGRF at 0.31-20 ng/ml and VEGF at 31.3-2,000 pg/ml). In this study we hope to answer several questions: (1) Are the limits of detection (LODs) reported for multiplex electrochemical biosensors of clinical relevance and how do they compare to well-established methods like ELISA, FISH, or PCR? (2) Can a single sensor electrode be used for the detection of multiple markers from one blood drop? (3) What mechanism of electrochemical biosensing is the most promising, and what technological advancements are needed to utilize these devices for multiplex POC detection? (4) Can nanotechnology advance the sensitive and selective diagnostics of multiple BC biomarkers? (5) Are there preferred receptors (antibody, nucleic acid or their combinations) and preferred biosensor designs (complementary methods, sandwich-type protocols, antibody/aptamer concept, label-free protocol)? (6) Why are we still without FDA-approved electrochemical multiplex devices for BC screening?

A Clinically Feasible Diagnostic Electrochemical Micronano Motors Biosensor Built on Miniature Swimmer for Multiplex Detection and Grading of Breast Cancer Biomarkers

Simultaneous Ultrasensitive Detection of Two Breast Cancer Microrna Biomarkers by Using a Dual Nanoparticle/nanosheet Fluorescence Resonance Energy Transfer Sensor

Smart enzyme-free amplification dual-mode self-powered platform designed on two-dimensional networked graphdiyne and DNA nanorods for ultra-sensitive detection of breast cancer biomarkers

High Fidelity Detection of miRNAs from Complex Physiological Samples Through Electrochemical Nanosensors Empowered by Proximity Catalysis and Magnetic Separation

Mg-based Micromotors for Efficient Electrochemical Detection of Circulating Tumor Cells

Self‐Propelled Nanoswimmers in Biomedical Sensing

Motor-based Autonomous Microsensor for Motion and Counting Immunoassay of Cancer Biomarker.

Electrochemical-Based Microrna Sensors

Advances in Electrochemical Biosensor Technologies for the Detection of Nucleic Acid Breast Cancer Biomarkers

Ultrasensitive electroluminescence biosensor for a breast cancer marker microRNA based on target cyclic regeneration and multi-labeled magnetized nanoparticles

Multiplex electrochemical sensing platforms for the detection of breast cancer biomarkers

Dna Nanostructure-Based Ultrasensitive Electrochemical Microrna Biosensor

Electrochemical Biosensors for the Non-invasive Diagnosis of Breast Cancer

Electrochemical Microfluidic Multiplexed Bioanalysis by a Highly Active Bottlebrush-like Nanocarbon Microelectrode

Novel Co MOF with Ionic Liquid Comprised Portable Molecularly Imprinted Polymer-Based Electrochemical Sensor for the Point-of-Care Detection of a Breast Cancer Biomarker

Cu-MOF/Aptamer/Magnetic Bead Sensor for Detection of Breast Cancer Biomarkers HER2 and ER

Metal–organic Frameworks (mofs) Based Electrochemical Biosensors for Early Cancer Diagnosis in Vitro

Constraint Coupling of Redox Cascade and Electron Transfer Synchronization on Electrode-Nanosensor Interface for Repeatable Detection of Tumor Biomarkers

(Invited) Nanoparticles Based Electrochemical Biosensors for the Detection of Tumor Cells and Associated Biomarkers

Advance in the application of MOF composites for breast cancer biomarkers sensing detection

Single-atom Cu-attached MOFs as peroxide-like enzymes to construct dual-mode immunosensors for detection of breast cancer typing in serum